PubMed:12174906 JSONTXT

{"project":"sentences","denotations":[{"id":"TextSentencer_T1","span":{"begin":0,"end":120},"obj":"Sentence"},{"id":"TextSentencer_T2","span":{"begin":121,"end":132},"obj":"Sentence"},{"id":"TextSentencer_T3","span":{"begin":133,"end":366},"obj":"Sentence"},{"id":"TextSentencer_T4","span":{"begin":367,"end":541},"obj":"Sentence"},{"id":"TextSentencer_T5","span":{"begin":542,"end":563},"obj":"Sentence"},{"id":"TextSentencer_T6","span":{"begin":564,"end":854},"obj":"Sentence"},{"id":"TextSentencer_T7","span":{"begin":855,"end":863},"obj":"Sentence"},{"id":"TextSentencer_T8","span":{"begin":864,"end":954},"obj":"Sentence"},{"id":"TextSentencer_T9","span":{"begin":955,"end":1152},"obj":"Sentence"},{"id":"TextSentencer_T10","span":{"begin":1153,"end":1164},"obj":"Sentence"},{"id":"TextSentencer_T11","span":{"begin":1165,"end":1317},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":120},"obj":"Sentence"},{"id":"T2","span":{"begin":121,"end":132},"obj":"Sentence"},{"id":"T3","span":{"begin":133,"end":366},"obj":"Sentence"},{"id":"T4","span":{"begin":367,"end":541},"obj":"Sentence"},{"id":"T5","span":{"begin":542,"end":563},"obj":"Sentence"},{"id":"T6","span":{"begin":564,"end":854},"obj":"Sentence"},{"id":"T7","span":{"begin":855,"end":863},"obj":"Sentence"},{"id":"T8","span":{"begin":864,"end":954},"obj":"Sentence"},{"id":"T9","span":{"begin":955,"end":1152},"obj":"Sentence"},{"id":"T10","span":{"begin":1153,"end":1164},"obj":"Sentence"},{"id":"T11","span":{"begin":1165,"end":1317},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Expression of COX-2 and Wnt pathway genes in adenomas of familial adenomatous polyposis patients treated with meloxicam.\nBACKGROUND: Familial adenomatous polyposis (FAP) is an autosomal, dominantly inherited predisposition to colorectal cancer caused by germline mutations within the adenomatous polyposis coli (APC) gene, a key member of the Wnt signalling pathway. A new class of non-steroidal anti-inflammatory drugs (NSAIDs), the specific cyclooxygenase 2 (COX-2) inhibitors, have recently been applied for the treatment of FAP patients.\nPATIENTS AND METHODS: The expressions of the Wnt members and targets APC, c-myc, cyclin D1 and COX-2, as measured by real-time quantitative RT-PCR, have been evaluated in fresh samples of normal colorectal mucosa and matched adenoma tissue of six unrelated FAP patients before and after treatment with meloxicam.\nRESULTS: A significant up-regulation of COX-2 in adenomas after treatment with meloxicam was found. Furthermore, in adenomas, a down-regulation of APC after treatment and a tight correlation of the expressions of the two Wnt targets, c-myc and cyclin D1, in both stages of treatment were observed.\nCONCLUSION: A feedback loop mediated by the peroxisome proliferator-activated receptor (PPAR) gamma is discussed as being responsible for the up-regulation of COX-2"}

{"project":"DisGeNET5_gene_disease","denotations":[{"id":"12174906-0#14#19#gene5743","span":{"begin":14,"end":19},"obj":"gene5743"},{"id":"12174906-0#57#87#diseaseC0032580","span":{"begin":57,"end":87},"obj":"diseaseC0032580"},{"id":"12174906-1#151#177#gene324","span":{"begin":284,"end":310},"obj":"gene324"},{"id":"12174906-1#179#182#gene324","span":{"begin":312,"end":315},"obj":"gene324"},{"id":"12174906-1#0#30#diseaseC0032580","span":{"begin":133,"end":163},"obj":"diseaseC0032580"}],"relations":[{"id":"14#19#gene574357#87#diseaseC0032580","pred":"associated_with","subj":"12174906-0#14#19#gene5743","obj":"12174906-0#57#87#diseaseC0032580"},{"id":"151#177#gene3240#30#diseaseC0032580","pred":"associated_with","subj":"12174906-1#151#177#gene324","obj":"12174906-1#0#30#diseaseC0032580"},{"id":"179#182#gene3240#30#diseaseC0032580","pred":"associated_with","subj":"12174906-1#179#182#gene324","obj":"12174906-1#0#30#diseaseC0032580"}],"text":"Expression of COX-2 and Wnt pathway genes in adenomas of familial adenomatous polyposis patients treated with meloxicam.\nBACKGROUND: Familial adenomatous polyposis (FAP) is an autosomal, dominantly inherited predisposition to colorectal cancer caused by germline mutations within the adenomatous polyposis coli (APC) gene, a key member of the Wnt signalling pathway. A new class of non-steroidal anti-inflammatory drugs (NSAIDs), the specific cyclooxygenase 2 (COX-2) inhibitors, have recently been applied for the treatment of FAP patients.\nPATIENTS AND METHODS: The expressions of the Wnt members and targets APC, c-myc, cyclin D1 and COX-2, as measured by real-time quantitative RT-PCR, have been evaluated in fresh samples of normal colorectal mucosa and matched adenoma tissue of six unrelated FAP patients before and after treatment with meloxicam.\nRESULTS: A significant up-regulation of COX-2 in adenomas after treatment with meloxicam was found. Furthermore, in adenomas, a down-regulation of APC after treatment and a tight correlation of the expressions of the two Wnt targets, c-myc and cyclin D1, in both stages of treatment were observed.\nCONCLUSION: A feedback loop mediated by the peroxisome proliferator-activated receptor (PPAR) gamma is discussed as being responsible for the up-regulation of COX-2"}

{"project":"DisGeNet-2017-sample","denotations":[{"id":"T61","span":{"begin":14,"end":19},"obj":"gene:5743"},{"id":"T62","span":{"begin":57,"end":87},"obj":"disease:C0032580"}],"relations":[{"id":"R1","pred":"associated_with","subj":"T61","obj":"T62"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"Expression of COX-2 and Wnt pathway genes in adenomas of familial adenomatous polyposis patients treated with meloxicam.\nBACKGROUND: Familial adenomatous polyposis (FAP) is an autosomal, dominantly inherited predisposition to colorectal cancer caused by germline mutations within the adenomatous polyposis coli (APC) gene, a key member of the Wnt signalling pathway. A new class of non-steroidal anti-inflammatory drugs (NSAIDs), the specific cyclooxygenase 2 (COX-2) inhibitors, have recently been applied for the treatment of FAP patients.\nPATIENTS AND METHODS: The expressions of the Wnt members and targets APC, c-myc, cyclin D1 and COX-2, as measured by real-time quantitative RT-PCR, have been evaluated in fresh samples of normal colorectal mucosa and matched adenoma tissue of six unrelated FAP patients before and after treatment with meloxicam.\nRESULTS: A significant up-regulation of COX-2 in adenomas after treatment with meloxicam was found. Furthermore, in adenomas, a down-regulation of APC after treatment and a tight correlation of the expressions of the two Wnt targets, c-myc and cyclin D1, in both stages of treatment were observed.\nCONCLUSION: A feedback loop mediated by the peroxisome proliferator-activated receptor (PPAR) gamma is discussed as being responsible for the up-regulation of COX-2"}

{"project":"UBERON-AE","denotations":[{"id":"PD-UBERON-AE-B_T1","span":{"begin":737,"end":754},"obj":"http://purl.obolibrary.org/obo/UBERON_0013067"},{"id":"PD-UBERON-AE-B_T2","span":{"begin":748,"end":754},"obj":"http://purl.obolibrary.org/obo/UBERON_0000344"},{"id":"PD-UBERON-AE-B_T3","span":{"begin":775,"end":781},"obj":"http://purl.obolibrary.org/obo/UBERON_0000479"}],"text":"Expression of COX-2 and Wnt pathway genes in adenomas of familial adenomatous polyposis patients treated with meloxicam.\nBACKGROUND: Familial adenomatous polyposis (FAP) is an autosomal, dominantly inherited predisposition to colorectal cancer caused by germline mutations within the adenomatous polyposis coli (APC) gene, a key member of the Wnt signalling pathway. A new class of non-steroidal anti-inflammatory drugs (NSAIDs), the specific cyclooxygenase 2 (COX-2) inhibitors, have recently been applied for the treatment of FAP patients.\nPATIENTS AND METHODS: The expressions of the Wnt members and targets APC, c-myc, cyclin D1 and COX-2, as measured by real-time quantitative RT-PCR, have been evaluated in fresh samples of normal colorectal mucosa and matched adenoma tissue of six unrelated FAP patients before and after treatment with meloxicam.\nRESULTS: A significant up-regulation of COX-2 in adenomas after treatment with meloxicam was found. Furthermore, in adenomas, a down-regulation of APC after treatment and a tight correlation of the expressions of the two Wnt targets, c-myc and cyclin D1, in both stages of treatment were observed.\nCONCLUSION: A feedback loop mediated by the peroxisome proliferator-activated receptor (PPAR) gamma is discussed as being responsible for the up-regulation of COX-2"}

{"project":"performance-test","denotations":[{"id":"PD-UBERON-AE-B_T1","span":{"begin":737,"end":754},"obj":"http://purl.obolibrary.org/obo/UBERON_0013067"},{"id":"PD-UBERON-AE-B_T2","span":{"begin":748,"end":754},"obj":"http://purl.obolibrary.org/obo/UBERON_0000344"},{"id":"PD-UBERON-AE-B_T3","span":{"begin":775,"end":781},"obj":"http://purl.obolibrary.org/obo/UBERON_0000479"}],"text":"Expression of COX-2 and Wnt pathway genes in adenomas of familial adenomatous polyposis patients treated with meloxicam.\nBACKGROUND: Familial adenomatous polyposis (FAP) is an autosomal, dominantly inherited predisposition to colorectal cancer caused by germline mutations within the adenomatous polyposis coli (APC) gene, a key member of the Wnt signalling pathway. A new class of non-steroidal anti-inflammatory drugs (NSAIDs), the specific cyclooxygenase 2 (COX-2) inhibitors, have recently been applied for the treatment of FAP patients.\nPATIENTS AND METHODS: The expressions of the Wnt members and targets APC, c-myc, cyclin D1 and COX-2, as measured by real-time quantitative RT-PCR, have been evaluated in fresh samples of normal colorectal mucosa and matched adenoma tissue of six unrelated FAP patients before and after treatment with meloxicam.\nRESULTS: A significant up-regulation of COX-2 in adenomas after treatment with meloxicam was found. Furthermore, in adenomas, a down-regulation of APC after treatment and a tight correlation of the expressions of the two Wnt targets, c-myc and cyclin D1, in both stages of treatment were observed.\nCONCLUSION: A feedback loop mediated by the peroxisome proliferator-activated receptor (PPAR) gamma is discussed as being responsible for the up-regulation of COX-2"}

{"project":"DisGeNET","denotations":[{"id":"T0","span":{"begin":14,"end":19},"obj":"gene:4513"},{"id":"T1","span":{"begin":57,"end":87},"obj":"disease:C0032580"},{"id":"T2","span":{"begin":14,"end":19},"obj":"gene:5743"},{"id":"T3","span":{"begin":45,"end":53},"obj":"disease:C0001430"},{"id":"T4","span":{"begin":14,"end":19},"obj":"gene:4513"},{"id":"T5","span":{"begin":45,"end":53},"obj":"disease:C0001430"},{"id":"T6","span":{"begin":14,"end":19},"obj":"gene:5743"},{"id":"T7","span":{"begin":57,"end":87},"obj":"disease:C0032580"},{"id":"T8","span":{"begin":312,"end":315},"obj":"gene:324"},{"id":"T9","span":{"begin":226,"end":243},"obj":"disease:C0009402"},{"id":"T10","span":{"begin":312,"end":315},"obj":"gene:324"},{"id":"T11","span":{"begin":165,"end":168},"obj":"disease:C0032580"},{"id":"T12","span":{"begin":312,"end":315},"obj":"gene:324"},{"id":"T13","span":{"begin":133,"end":163},"obj":"disease:C0032580"},{"id":"T14","span":{"begin":284,"end":310},"obj":"gene:324"},{"id":"T15","span":{"begin":133,"end":163},"obj":"disease:C0032580"},{"id":"T16","span":{"begin":312,"end":315},"obj":"gene:324"},{"id":"T17","span":{"begin":226,"end":243},"obj":"disease:C1527249"},{"id":"T18","span":{"begin":461,"end":466},"obj":"gene:5743"},{"id":"T19","span":{"begin":528,"end":531},"obj":"disease:C0032580"},{"id":"T20","span":{"begin":895,"end":900},"obj":"gene:5743"},{"id":"T21","span":{"begin":904,"end":912},"obj":"disease:C0001430"}],"relations":[{"id":"R1","pred":"associated_with","subj":"T0","obj":"T1"},{"id":"R2","pred":"associated_with","subj":"T2","obj":"T3"},{"id":"R3","pred":"associated_with","subj":"T4","obj":"T5"},{"id":"R4","pred":"associated_with","subj":"T6","obj":"T7"},{"id":"R5","pred":"associated_with","subj":"T8","obj":"T9"},{"id":"R6","pred":"associated_with","subj":"T10","obj":"T11"},{"id":"R7","pred":"associated_with","subj":"T12","obj":"T13"},{"id":"R8","pred":"associated_with","subj":"T14","obj":"T15"},{"id":"R9","pred":"associated_with","subj":"T16","obj":"T17"},{"id":"R10","pred":"associated_with","subj":"T18","obj":"T19"},{"id":"R11","pred":"associated_with","subj":"T20","obj":"T21"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"Expression of COX-2 and Wnt pathway genes in adenomas of familial adenomatous polyposis patients treated with meloxicam.\nBACKGROUND: Familial adenomatous polyposis (FAP) is an autosomal, dominantly inherited predisposition to colorectal cancer caused by germline mutations within the adenomatous polyposis coli (APC) gene, a key member of the Wnt signalling pathway. A new class of non-steroidal anti-inflammatory drugs (NSAIDs), the specific cyclooxygenase 2 (COX-2) inhibitors, have recently been applied for the treatment of FAP patients.\nPATIENTS AND METHODS: The expressions of the Wnt members and targets APC, c-myc, cyclin D1 and COX-2, as measured by real-time quantitative RT-PCR, have been evaluated in fresh samples of normal colorectal mucosa and matched adenoma tissue of six unrelated FAP patients before and after treatment with meloxicam.\nRESULTS: A significant up-regulation of COX-2 in adenomas after treatment with meloxicam was found. Furthermore, in adenomas, a down-regulation of APC after treatment and a tight correlation of the expressions of the two Wnt targets, c-myc and cyclin D1, in both stages of treatment were observed.\nCONCLUSION: A feedback loop mediated by the peroxisome proliferator-activated receptor (PPAR) gamma is discussed as being responsible for the up-regulation of COX-2"}